Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy

Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity

(2016) Ronit Mazor et al.   Oncotarget

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

YAP Promotes Malignant Progression ofLkb1-Deficient Lung Adenocarcinoma through Downstream Regulation of Survivin

(2015) Wenjing Zhang et al.   CANCER RESEARCH

MoFvAb: Modeling the Fv region of antibodies

(2015) Alexander Bujotzek et al.   mAbs

Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors

(2015) R. Mazor et al.   MOLECULAR CANCER THERAPEUTICS

Advances in Anticancer Immunotoxin Therapy

(2015) C. Alewine et al.   ONCOLOGIST

High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis

(2015) Anish Thomas et al.   Oncotarget

Targeting Bcl-2 stability to sensitize cells harboring oncogenic ras

(2015) Bo Peng et al.   Oncotarget

Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results

(2015) Emily Mason-Osann et al.   Scientific Reports

Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy

(2014) I. Pastan et al.   CANCER RESEARCH

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

(2014) Mark G. Kris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer

(2014) K. Hollevoet et al.   MOLECULAR CANCER THERAPEUTICS

Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers

(2014) C. Alewine et al.   MOLECULAR CANCER THERAPEUTICS

Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse Models

(2013) D. Siolas et al.   CANCER RESEARCH

Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development

(2012) R. J. Kelly et al.   MOLECULAR CANCER THERAPEUTICS

A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity

(2012) J. E. Weldon et al.   MOLECULAR CANCER THERAPEUTICS

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes

(2012) W. Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Flow Cytometry Method to Quantitate Internalized Immunotoxins Shows that Taxol Synergistically Increases Cellular Immunotoxins Uptake

(2010) Y. Zhang et al.   CANCER RESEARCH

Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics☆

(2009) Satoshi Nagata et al.   ADVANCED DRUG DELIVERY REVIEWS

Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P

(2009) R. J. Kreitman et al.   CLINICAL CANCER RESEARCH

A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity

(2008) J. E. Weldon et al.   BLOOD

Establishment of Patient-Derived Non-Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers

(2008) I. Fichtner et al.   CLINICAL CANCER RESEARCH

An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes

(2008) M. Onda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The current state of serum biomarkers of hepatotoxicity

(2007) Josef Ozer et al.   TOXICOLOGY